VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2022 | Final results of DUOGLOBE: real-world evidence for LGIC in advanced Parkinson’s disease

K. Ray-Chaudhuri, MD, DSc, FRCP, FEAN, King’s College London, London, UK, presented the final analysis of the DUOGLOBE study (NCT02611713) at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria. The study was a two-year, international prospective registry of real-life data collected from patients with advanced Parkinson’s disease (PD), treated with intrajejunal levodopa-carbidopa infusion in routine clinical practice. Several clinical trials of levodopa-carbidopa intestinal gel (LGIC) have documented its efficacy against motor and non-motor symptoms in advanced stages of disease, but long-term data on its real-world use is limited. In DUOGLOBE, long-term motor function and non-motor symptoms (e.g. quality of life) were analyzed over the two-year follow-up, in addition to data on caregiver stress. The data showed sustained and consistent improvements in motor function and non-motor function, such as sleep, mood, pain, and gastrointestinal symptoms across two years. Additionally, caregivers’ strain and patients’ quality of life improved.